



March 27, 2017  
FOR 8:30 AM RELEASE  
CSE: TBP

## ***Tetra Bio-Pharma Appoints Edward Miller as Vice President, Investor Relations & Corporate Communications***

**Ottawa, Ontario - (Marketwired – March 27, 2017)** –Tetra Bio-Pharma Inc. (“**Tetra**” or the “**Company**”) (CSE:TBP) (OTCPINK:GRPOF), today announced that it entered into an employment agreement with Edward Miller as Vice President, Investor Relations and Corporate Communications effective today.

Mr. Miller has over a decade of experience in the Biotech/Pharma industry. Most recently, he served as Director, Investor Relations and Corporate Communications at IntelGenx Corp. where he successfully built their shareholder communications program, resulting in substantial growth in their website traffic and social media hits. Mr. Miller joined Paladin Labs in 2001 where he held various positions including Manager, Investor Relations where he successfully built their investor relations program. Following his tenure at Paladin Labs he moved into the role as an investor relations consultant working for Christensen IR, heading their life science practice and as an independent where he has built award winning investor relations programs. Mr. Miller is the Past President of CIRI (Canadian Investor Relations Institute) Quebec Chapter where he served two terms (2009 – 2012) and (2005 – 2007). Mr. Miller will be contributing to improving the company’s visibility in the capital markets and leveraging his international experience at broadening its shareholder base.

“We are most pleased to welcome Edward to the team as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “Mr. Miller has built award winning investor relations programs that have driven shareholder value and visibility for several organizations in the market place. We look forward to expanding our communications outreach as we build an even stronger shareholder base moving forwards.”

### **About Tetra Bio-Pharma:**

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE: TBP) (OTCPINK: GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: [www.tetrabiopharma.com](http://www.tetrabiopharma.com).

**For further information, please contact Tetra Bio-Pharma Inc.**

Dr. Guy Chamberland  
Chief Science Officer  
Phone: (514) 220-9225

André Rancourt  
Chief Executive Officer  
Phone: (343) 689-0714

*The Canadian Securities Exchange ("CSE") has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.*

**Forward-looking statements**

*Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.*